Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the drugmaker’s cancer treatment offerings. The acquisition was for a total equity value of about $4.1 billion, at $62.50 per share. RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company, has several cancer treatments under development, specifically ones targeting the treatment…
Johnson & Johnson announced that it has applied to the FDA for approval of Rybrevant in combination with lazertinib as a first-line treatment for adult patients with EGFR-mutated locally advanced or...
News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor...
A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.
In this article, Cerba details how AI and image analysis were using in the quantification of Ki-67 in solidtumors.